TC-2216
 | |
| Identifiers | |
|---|---|
| |
| PubChem (CID) | 10176607 |
| ChemSpider | 8352112 |
| Chemical and physical data | |
| Formula | C12H17N3 |
| Molar mass | 203.283 |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and is being researched for the treatment of anxiety and depression.[1]
References
- ↑ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| 5-HT1A agonists | |
|---|---|
| GABAAR PAMs |
|
| α2δ VDCC blockers | |
| Antidepressants |
|
| Sympatholytics | |
| Others | |
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.